Cara Therapeutics Reports Exit/Disposal Costs
Ticker: TVRD · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Cara Therapeutics, Inc. (TVRD) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $2.6 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, cost-reduction
Related Tickers: CARA
TL;DR
Cara Therapeutics is cutting costs related to exiting or disposing of operations.
AI Summary
Cara Therapeutics, Inc. filed an 8-K on June 18, 2024, reporting costs associated with exit or disposal activities as of June 14, 2024. The filing indicates the company is undergoing restructuring or winding down certain operations, though specific financial details of these costs are not yet disclosed in this initial report.
Why It Matters
This filing suggests Cara Therapeutics is undergoing significant operational changes, potentially impacting its future business strategy and financial outlook.
Risk Assessment
Risk Level: medium — The filing indicates restructuring or disposal of activities, which can introduce uncertainty about the company's future operations and financial health.
Key Players & Entities
- Cara Therapeutics, Inc. (company) — Registrant
- June 14, 2024 (date) — Date of earliest event reported
- June 18, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 001-36279 (identifier) — Commission File Number
FAQ
What specific activities are being exited or disposed of by Cara Therapeutics?
The filing does not specify the exact activities being exited or disposed of, only that costs are associated with these actions.
When did the costs associated with exit or disposal activities begin?
The earliest event reported related to these costs is dated June 14, 2024.
What is the total financial impact of these exit or disposal costs?
The filing does not disclose the specific dollar amounts of the costs associated with exit or disposal activities.
Is this filing related to a specific product or business segment?
The filing does not provide details on specific products or business segments affected by the exit or disposal activities.
What is the purpose of filing this 8-K report?
The purpose is to report costs associated with exit or disposal activities as required by Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 773 words · 3 min read · ~3 pages · Grade level 14.1 · Accepted 2024-06-18 16:16:03
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CARA The Nasdaq Stock Marke
- $2.6 million — y anticipates recognizing approximately $2.6 million in total charges in connection with the
Filing Documents
- tm2417536d1_8k.htm (8-K) — 25KB
- 0001104659-24-072821.txt ( ) — 195KB
- cara-20240614.xsd (EX-101.SCH) — 3KB
- cara-20240614_lab.xml (EX-101.LAB) — 33KB
- cara-20240614_pre.xml (EX-101.PRE) — 22KB
- tm2417536d1_8k_htm.xml (XML) — 4KB
05
Item 2.05. Costs Associated with Exit or Disposal Activities. On June 14, 2024, the Board of Directors of Cara Therapeutics, Inc. (the "Company") approved a streamlined operating plan exploring strategic alternatives focused on maximizing shareholder value after the Company announced its decision to discontinue the clinical program in notalgia paresthetica ("NP") following the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with NP on June 12, 2024. In connection with the streamlined operating plan, the Board of Directors also approved a reduction in the Company's workforce by approximately 70%, which the Company expects to substantially complete by June 30, 2024. The Company anticipates recognizing approximately $2.6 million in total charges in connection with the reduction in force, which costs are expected to be substantially recognized in the second and third quarter of 2024. These charges will consist primarily of one-time cash charges for termination benefits. The charges the Company expects to incur in connection with this reduction in workforce are subject to a number of assumptions, risks and uncertainties, and actual results may materially differ. The Company may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, these actions.
Forward-Looking Statements
Forward-Looking Statements historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company's streamlined operating plan, the expected costs of the reduction in force and the timing of recognition of such charges. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include the risks inherent in the clinical and regulatory development of pharmaceutical products, and the risks described more fully in Cara Therapeutics' filings with the Securities and Exchange Commission, including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ending December 31, 2023 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2024. All forward-looking statements contained in this report speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARA THERAPEUTICS, INC. By: /s/ RYAN MAYNARD Ryan Maynard Chief Financial Officer (Principal Financial and Accounting Officer) Date: June 18, 2024